CN115697992A - 一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用 - Google Patents
一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用 Download PDFInfo
- Publication number
- CN115697992A CN115697992A CN202180040988.2A CN202180040988A CN115697992A CN 115697992 A CN115697992 A CN 115697992A CN 202180040988 A CN202180040988 A CN 202180040988A CN 115697992 A CN115697992 A CN 115697992A
- Authority
- CN
- China
- Prior art keywords
- substituted
- alkyl
- compound
- membered
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 95
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 108010080146 androgen receptors Proteins 0.000 title description 31
- 102000001307 androgen receptors Human genes 0.000 title description 31
- 230000002401 inhibitory effect Effects 0.000 title description 8
- 230000000593 degrading effect Effects 0.000 title description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 239000013078 crystal Substances 0.000 claims abstract description 30
- 229940002612 prodrug Drugs 0.000 claims abstract description 29
- 239000000651 prodrug Substances 0.000 claims abstract description 29
- 239000012453 solvate Substances 0.000 claims abstract description 29
- 239000002207 metabolite Substances 0.000 claims abstract description 28
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 17
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 128
- 125000001424 substituent group Chemical group 0.000 claims description 103
- -1 cyclobutyl spiropiperidine Chemical compound 0.000 claims description 93
- 229910052739 hydrogen Inorganic materials 0.000 claims description 84
- 229910052731 fluorine Inorganic materials 0.000 claims description 81
- 229910052740 iodine Inorganic materials 0.000 claims description 71
- 125000003545 alkoxy group Chemical group 0.000 claims description 68
- 125000001072 heteroaryl group Chemical group 0.000 claims description 44
- 125000000623 heterocyclic group Chemical group 0.000 claims description 42
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 33
- 125000005842 heteroatom Chemical group 0.000 claims description 31
- 229910052799 carbon Inorganic materials 0.000 claims description 29
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 22
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- 230000005764 inhibitory process Effects 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 230000015556 catabolic process Effects 0.000 claims description 9
- 238000006731 degradation reaction Methods 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000001602 bicycloalkyls Chemical group 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 230000005496 eutectics Effects 0.000 abstract description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 191
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- 238000006243 chemical reaction Methods 0.000 description 59
- 239000000243 solution Substances 0.000 description 56
- 230000002829 reductive effect Effects 0.000 description 52
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical group C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 40
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 30
- 239000000543 intermediate Substances 0.000 description 29
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 27
- 238000010898 silica gel chromatography Methods 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 239000012043 crude product Substances 0.000 description 25
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 22
- 239000000126 substance Substances 0.000 description 21
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 14
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 13
- 125000003003 spiro group Chemical group 0.000 description 13
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 12
- 108091008715 AR-FL Proteins 0.000 description 11
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- MPQLCQKBYRSPNA-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione Chemical compound O=C1C2=CC(F)=CC=C2C(=O)N1C1CCC(=O)NC1=O MPQLCQKBYRSPNA-UHFFFAOYSA-N 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000012065 filter cake Substances 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 150000002367 halogens Chemical group 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 8
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XQTGLKJTKXDCIX-UHFFFAOYSA-N 2-[4-[1-(2-azaspiro[3.5]nonan-7-yl)piperidin-4-yl]pyrazol-1-yl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methylpropanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C(CC2)CCN2C2CCC3(CNC3)CC2)=C1 XQTGLKJTKXDCIX-UHFFFAOYSA-N 0.000 description 7
- OYZSQLJFZDYNMA-UHFFFAOYSA-N 2-[4-[2-(azetidin-3-yl)ethynyl]pyrazol-1-yl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methylpropanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C#CC2CNC2)=C1 OYZSQLJFZDYNMA-UHFFFAOYSA-N 0.000 description 7
- HXOTVNAOPQHDEQ-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-2-(4-iodopyrazol-1-yl)-2-methylpropanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(I)=C1 HXOTVNAOPQHDEQ-UHFFFAOYSA-N 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- AHHALPZTMLZRFL-UHFFFAOYSA-N tert-butyl 3-[2-(1H-pyrazol-4-yl)ethynyl]azetidine-1-carboxylate Chemical compound CC(C)(C)OC(N(C1)CC1C#CC1=CNN=C1)=O AHHALPZTMLZRFL-UHFFFAOYSA-N 0.000 description 7
- FHOAMMMPWZMNLM-UHFFFAOYSA-N tert-butyl 4-(1H-pyrazol-4-yl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=CC1)C1=CNN=C1 FHOAMMMPWZMNLM-UHFFFAOYSA-N 0.000 description 7
- NSPSFSOMUZBHPB-UHFFFAOYSA-N tert-butyl 4-(1h-pyrazol-4-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CNN=C1 NSPSFSOMUZBHPB-UHFFFAOYSA-N 0.000 description 7
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 7
- QUERMGFVJPRMJL-UHFFFAOYSA-N tert-butyl azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC1 QUERMGFVJPRMJL-UHFFFAOYSA-N 0.000 description 7
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 6
- SOXIPNKHMJEZMN-UHFFFAOYSA-N 3-ethynylazetidine Chemical compound C#CC1CNC1 SOXIPNKHMJEZMN-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- OBARMWKFMOJVJE-UHFFFAOYSA-N tert-butyl 3-[2-[1-[1-[[4-cyano-3-(trifluoromethyl)phenyl]carbamoyl]cyclobutyl]pyrazol-4-yl]ethynyl]azetidine-1-carboxylate Chemical compound CC(C)(C)OC(N(C1)CC1C#CC1=CN(C2(CCC2)C(NC(C=C2)=CC(C(F)(F)F)=C2C#N)=O)N=C1)=O OBARMWKFMOJVJE-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 5
- 101150003085 Pdcl gene Proteins 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 238000012054 celltiter-glo Methods 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229940125773 compound 10 Drugs 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- TZOZEFROZVMDME-UHFFFAOYSA-N tert-butyl 3-[2-[1-[1-[4-cyano-3-(trifluoromethyl)anilino]-2-methyl-1-oxopropan-2-yl]pyrazol-4-yl]ethynyl]azetidine-1-carboxylate Chemical compound CC(C)(C)OC(N(C1)CC1C#CC1=CN(C(C)(C)C(NC(C=C2)=CC(C(F)(F)F)=C2C#N)=O)N=C1)=O TZOZEFROZVMDME-UHFFFAOYSA-N 0.000 description 5
- UENGYBYGCXKNRF-UHFFFAOYSA-N tert-butyl 3-ethynylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(C#C)C1 UENGYBYGCXKNRF-UHFFFAOYSA-N 0.000 description 5
- 125000003396 thiol group Chemical class [H]S* 0.000 description 5
- LLNQWPTUJJYTTE-UHFFFAOYSA-N 4-iodopyrazole Chemical compound IC=1C=NNC=1 LLNQWPTUJJYTTE-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000005110 aryl thio group Chemical group 0.000 description 4
- 125000004452 carbocyclyl group Chemical group 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 4
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 4
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- BBKNAKDKYGLEKG-UHFFFAOYSA-N tert-butyl 3-[3-[2-[1-[1-[[4-cyano-3-(trifluoromethyl)phenyl]carbamoyl]cyclobutyl]pyrazol-4-yl]ethynyl]azetidin-1-yl]azetidine-1-carboxylate Chemical compound CC(C)(C)OC(N(C1)CC1N(C1)CC1C#CC1=CN(C2(CCC2)C(NC(C=C2)=CC(C(F)(F)F)=C2C#N)=O)N=C1)=O BBKNAKDKYGLEKG-UHFFFAOYSA-N 0.000 description 4
- SEQODMNFJCMZDP-UHFFFAOYSA-N tert-butyl 3-[[4-[1-[1-[4-cyano-3-(trifluoromethyl)anilino]-2-methyl-1-oxopropan-2-yl]pyrazol-4-yl]piperidin-1-yl]methyl]pyrrole-1-carboxylate Chemical compound CC(C)(C)OC(N1C=C(CN(CC2)CCC2C2=CN(C(C)(C)C(NC(C=C3)=CC(C(F)(F)F)=C3C#N)=O)N=C2)C=C1)=O SEQODMNFJCMZDP-UHFFFAOYSA-N 0.000 description 4
- RHPSCFZLRLQYHQ-UHFFFAOYSA-N tert-butyl 4-[2-[1-[1-[4-cyano-3-(trifluoromethyl)anilino]-2-methyl-1-oxopropan-2-yl]pyrazol-4-yl]ethynyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(N(CC1)CCC1C#CC1=CN(C(C)(C)C(NC(C=C2)=CC(C(F)(F)F)=C2C#N)=O)N=C1)=O RHPSCFZLRLQYHQ-UHFFFAOYSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 4
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- XQKTYFMSTDHVAL-UHFFFAOYSA-N 1-bromo-N-[4-cyano-3-(trifluoromethyl)phenyl]cyclobutane-1-carboxamide Chemical compound BrC1(CCC1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F XQKTYFMSTDHVAL-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 210000005267 prostate cell Anatomy 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- XMYHJUPBYREXHW-UHFFFAOYSA-N tert-butyl 4-[1-[1-[4-cyano-3-(trifluoromethyl)anilino]-2-methyl-1-oxopropan-2-yl]pyrazol-4-yl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(N(CC1)CCC1C1=CN(C(C)(C)C(NC(C=C2)=CC(C(F)(F)F)=C2C#N)=O)N=C1)=O XMYHJUPBYREXHW-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- VQBDZJOQOOMNRZ-UHFFFAOYSA-N 1-(4-iodopyrazol-1-yl)ethanone Chemical compound CC(=O)N1C=C(I)C=N1 VQBDZJOQOOMNRZ-UHFFFAOYSA-N 0.000 description 2
- CZTWHJUBUPTECG-RCWSMNMCSA-N 2-[4-[1-[(3aS,6aR)-2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]piperidin-4-yl]pyrazol-1-yl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methylpropanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C(CC2)CCN2C(C2)C[C@@H](C3)[C@H]2CN3C(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)=C1 CZTWHJUBUPTECG-RCWSMNMCSA-N 0.000 description 2
- HOJKCVDVQUGGGJ-UHFFFAOYSA-N 2-bromo-n-[4-cyano-3-(trifluoromethyl)phenyl]-2-methylpropanamide Chemical compound CC(C)(Br)C(=O)NC1=CC=C(C#N)C(C(F)(F)F)=C1 HOJKCVDVQUGGGJ-UHFFFAOYSA-N 0.000 description 2
- CRKGOGOZHZZJGR-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CC(C1)N2CC(C2)C#C Chemical compound CC(C)(C)OC(=O)N1CC(C1)N2CC(C2)C#C CRKGOGOZHZZJGR-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- JFNQBQOXQOVCKV-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-1-(4-piperidin-4-ylpyrazol-1-yl)cyclobutane-1-carboxamide Chemical compound N#CC(C=C1)=C(C(F)(F)F)C=C1NC(C1(CCC1)N1N=CC(C2CCNCC2)=C1)=O JFNQBQOXQOVCKV-UHFFFAOYSA-N 0.000 description 2
- VMOWYIMCFIYWFF-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[4-[1-[[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]pyrrolidin-3-yl]methyl]piperidin-4-yl]pyrazol-1-yl]cyclobutane-1-carboxamide Chemical compound N#CC(C=C1)=C(C(F)(F)F)C=C1NC(C1(CCC1)N1N=CC(C2CCN(CC(CC3)CN3C(C=C3C(N4C(CCC(N5)=O)C5=O)=O)=CC=C3C4=O)CC2)=C1)=O VMOWYIMCFIYWFF-UHFFFAOYSA-N 0.000 description 2
- LVHOEJMKTKXNAH-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[4-[2-[1-[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]azetidin-3-yl]azetidin-3-yl]ethynyl]pyrazol-1-yl]cyclobutane-1-carboxamide Chemical compound N#CC(C=C1)=C(C(F)(F)F)C=C1NC(C1(CCC1)N1N=CC(C#CC(C2)CN2C(C2)CN2C(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)=C1)=O LVHOEJMKTKXNAH-UHFFFAOYSA-N 0.000 description 2
- UTVNAZSZXPAUSJ-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[4-[2-[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]azetidin-3-yl]ethynyl]pyrazol-1-yl]cyclobutane-1-carboxamide Chemical compound N#CC(C=C1)=C(C(F)(F)F)C=C1NC(C1(CCC1)N1N=CC(C#CC(C2)CN2C(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)=C1)=O UTVNAZSZXPAUSJ-UHFFFAOYSA-N 0.000 description 2
- DJVIBZRFPYMAEU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-2-[4-[1-[[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]pyrrolidin-3-yl]methyl]piperidin-4-yl]pyrazol-1-yl]-2-methylpropanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C2CCN(CC(CC3)CN3C(C=C3C(N4C(CCC(N5)=O)C5=O)=O)=CC=C3C4=O)CC2)=C1 DJVIBZRFPYMAEU-UHFFFAOYSA-N 0.000 description 2
- IVWROKSXKCRQOZ-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-2-[4-[2-[1-[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]azetidin-3-yl]azetidin-3-yl]ethynyl]pyrazol-1-yl]-2-methylpropanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C#CC(C2)CN2C(C2)CN2C(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)=C1 IVWROKSXKCRQOZ-UHFFFAOYSA-N 0.000 description 2
- WKCISRMXSDRFQR-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-2-[4-[2-[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]azetidin-3-yl]ethynyl]pyrazol-1-yl]-2-methylpropanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C#CC(C2)CN2C(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)=C1 WKCISRMXSDRFQR-UHFFFAOYSA-N 0.000 description 2
- AUQJYWDHGFVVGE-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-2-[4-[2-[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperidin-4-yl]ethynyl]pyrazol-1-yl]-2-methylpropanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C#CC(CC2)CCN2C(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)=C1 AUQJYWDHGFVVGE-UHFFFAOYSA-N 0.000 description 2
- SUWMGSZFMUWYGT-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyl-2-(4-piperidin-4-ylpyrazol-1-yl)propanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C2CCNCC2)=C1 SUWMGSZFMUWYGT-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 2
- 229960004671 enzalutamide Drugs 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- FDDQRDMHICUGQC-UHFFFAOYSA-M pyrrole-1-carboxylate Chemical compound [O-]C(=O)N1C=CC=C1 FDDQRDMHICUGQC-UHFFFAOYSA-M 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- SRCROGUSYNRTRE-UHFFFAOYSA-N tert-butyl 3-formylpyrrole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=CC(C=O)=C1 SRCROGUSYNRTRE-UHFFFAOYSA-N 0.000 description 2
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- KKFDJZZADQONDE-UHFFFAOYSA-N (hydridonitrato)hydroxidocarbon(.) Chemical compound O[C]=N KKFDJZZADQONDE-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical group CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- XJUNJTHFEWUGFM-UHFFFAOYSA-N 1-[4-[2-(azetidin-3-yl)ethynyl]pyrazol-1-yl]-N-[4-cyano-3-(trifluoromethyl)phenyl]cyclobutane-1-carboxamide Chemical compound N#CC(C=C1)=C(C(F)(F)F)C=C1NC(C1(CCC1)N1N=CC(C#CC2CNC2)=C1)=O XJUNJTHFEWUGFM-UHFFFAOYSA-N 0.000 description 1
- PLECZQPTGCRYEY-UHFFFAOYSA-N 1-[4-[2-[1-(azetidin-3-yl)azetidin-3-yl]ethynyl]pyrazol-1-yl]-N-[4-cyano-3-(trifluoromethyl)phenyl]cyclobutane-1-carboxamide Chemical compound N#CC(C=C1)=C(C(F)(F)F)C=C1NC(C1(CCC1)N1N=CC(C#CC(C2)CN2C2CNC2)=C1)=O PLECZQPTGCRYEY-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- KLZAHUJTOHCAGX-DETIRCLXSA-N 2-[4-[1-[(3aR,6aS)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-5-yl]piperidin-4-yl]pyrazol-1-yl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methylpropanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C(CC2)CCN2C(C2)C[C@@H]3[C@H]2CNC3)=C1 KLZAHUJTOHCAGX-DETIRCLXSA-N 0.000 description 1
- XOSZNANYQWTRDC-UHFFFAOYSA-N 2-[4-[2-[1-(azetidin-3-yl)azetidin-3-yl]ethynyl]pyrazol-1-yl]-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methylpropanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C#CC(C2)CN2C2CNC2)=C1 XOSZNANYQWTRDC-UHFFFAOYSA-N 0.000 description 1
- OMNLKHUIGCZRQQ-UHFFFAOYSA-N 3-ethynylazetidine;hydrochloride Chemical compound Cl.C#CC1CNC1 OMNLKHUIGCZRQQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BELMWZRHFIICRC-UHFFFAOYSA-N CC(C)(C)OC(C(C1)CC1C(C1)CC1C#C)=O Chemical compound CC(C)(C)OC(C(C1)CC1C(C1)CC1C#C)=O BELMWZRHFIICRC-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000272186 Falco columbarius Species 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PJFIFZOFPMAGRL-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-1-(4-iodopyrazol-1-yl)cyclobutane-1-carboxamide Chemical compound N#CC(C=C1)=C(C(F)(F)F)C=C1NC(C1(CCC1)N1N=CC(I)=C1)=O PJFIFZOFPMAGRL-UHFFFAOYSA-N 0.000 description 1
- PJGRWPPAXNLXHL-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-1-[4-[1-(pyrrolidin-3-ylmethyl)piperidin-4-yl]pyrazol-1-yl]cyclobutane-1-carboxamide Chemical compound N#CC(C=C1)=C(C(F)(F)F)C=C1NC(C1(CCC1)N1N=CC(C2CCN(CC3CNCC3)CC2)=C1)=O PJGRWPPAXNLXHL-UHFFFAOYSA-N 0.000 description 1
- IQBNRIHJWOKCCX-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-2-[4-[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperidin-4-yl]pyrazol-1-yl]-2-methylpropanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C(CC2)CCN2C(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)=C1 IQBNRIHJWOKCCX-UHFFFAOYSA-N 0.000 description 1
- KRMOGKPMTQWBIT-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyl-2-[4-(2-piperidin-4-ylethynyl)pyrazol-1-yl]propanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C#CC2CCNCC2)=C1 KRMOGKPMTQWBIT-UHFFFAOYSA-N 0.000 description 1
- CDBWWYIXMFBDKX-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyl-2-[4-[1-(pyrrolidin-3-ylmethyl)piperidin-4-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)(C(NC(C=C1)=CC(C(F)(F)F)=C1C#N)=O)N1N=CC(C2CCN(CC3CNCC3)CC2)=C1 CDBWWYIXMFBDKX-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 208000037842 advanced-stage tumor Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZAEBLFKQMDEPDM-UHFFFAOYSA-N cyclobutyl radical Chemical compound [CH]1CCC1 ZAEBLFKQMDEPDM-UHFFFAOYSA-N 0.000 description 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 1
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 108010026668 snake venom protein C activator Proteins 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- ANTJOSVSOKPUCF-XZQOPNAISA-N tert-butyl (3aR,6aS)-5-[4-[1-[1-[4-cyano-3-(trifluoromethyl)anilino]-2-methyl-1-oxopropan-2-yl]pyrazol-4-yl]piperidin-1-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxylate Chemical compound CC(C)(C)OC(N1C[C@H](CC(C2)N(CC3)CCC3C3=CN(C(C)(C)C(NC(C=C4)=CC(C(F)(F)F)=C4C#N)=O)N=C3)[C@H]2C1)=O ANTJOSVSOKPUCF-XZQOPNAISA-N 0.000 description 1
- LGHAAAIUUYWURJ-UHFFFAOYSA-N tert-butyl 1h-pyrrole-2-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=CN1 LGHAAAIUUYWURJ-UHFFFAOYSA-N 0.000 description 1
- MVBJELSNUFREQL-UHFFFAOYSA-N tert-butyl 3-[2-(1-acetylpyrazol-4-yl)ethynyl]azetidine-1-carboxylate Chemical compound CC(C)(C)OC(N(C1)CC1C#CC1=CN(C(C)=O)N=C1)=O MVBJELSNUFREQL-UHFFFAOYSA-N 0.000 description 1
- QQBUAKATDZITBF-UHFFFAOYSA-N tert-butyl 3-[3-[2-[1-[1-[4-cyano-3-(trifluoromethyl)anilino]-2-methyl-1-oxopropan-2-yl]pyrazol-4-yl]ethynyl]azetidin-1-yl]azetidine-1-carboxylate Chemical compound CC(C)(C)OC(N(C1)CC1N(C1)CC1C#CC1=CN(C(C)(C)C(NC(C=C2)=CC(C(F)(F)F)=C2C#N)=O)N=C1)=O QQBUAKATDZITBF-UHFFFAOYSA-N 0.000 description 1
- HFWBOQGFRDSJBY-UHFFFAOYSA-N tert-butyl 3-[[4-[1-[1-[4-cyano-3-(trifluoromethyl)anilino]-2-methyl-1-oxopropan-2-yl]pyrazol-4-yl]piperidin-1-yl]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(N1CC(CN(CC2)CCC2C2=CN(C(C)(C)C(NC(C=C3)=CC(C(F)(F)F)=C3C#N)=O)N=C2)CC1)=O HFWBOQGFRDSJBY-UHFFFAOYSA-N 0.000 description 1
- YQTBNGOMJGLOSE-UHFFFAOYSA-N tert-butyl 3-[[4-[1-[1-[[4-cyano-3-(trifluoromethyl)phenyl]carbamoyl]cyclobutyl]pyrazol-4-yl]piperidin-1-yl]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(N1CC(CN(CC2)CCC2C2=CN(C3(CCC3)C(NC(C=C3)=CC(C(F)(F)F)=C3C#N)=O)N=C2)CC1)=O YQTBNGOMJGLOSE-UHFFFAOYSA-N 0.000 description 1
- VMKIXWAFFVLJCK-UHFFFAOYSA-N tert-butyl 3-oxoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C1 VMKIXWAFFVLJCK-UHFFFAOYSA-N 0.000 description 1
- INUWDZDWSJJFSQ-UHFFFAOYSA-N tert-butyl 4-ethynylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C#C)CC1 INUWDZDWSJJFSQ-UHFFFAOYSA-N 0.000 description 1
- TXJZGBNZYYZAQB-UHFFFAOYSA-N tert-butyl 7-[4-[1-[1-[4-cyano-3-(trifluoromethyl)anilino]-2-methyl-1-oxopropan-2-yl]pyrazol-4-yl]piperidin-1-yl]-2-azaspiro[3.5]nonane-2-carboxylate Chemical compound CC(C)(C)OC(N(C1)CC1(CC1)CCC1N(CC1)CCC1C1=CN(C(C)(C)C(NC(C=C2)=CC(C(F)(F)F)=C2C#N)=O)N=C1)=O TXJZGBNZYYZAQB-UHFFFAOYSA-N 0.000 description 1
- KHCPHQZPEYFYRA-UHFFFAOYSA-N tert-butyl 7-oxo-2-azaspiro[3.5]nonane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CCC(=O)CC2 KHCPHQZPEYFYRA-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
提供了一种通式B‑L‑K(I)所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶，及其中间体，以及在AR相关疾病如前列腺癌中的用途。
Description
PCT国内申请，说明书已公开。
Claims (12)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020106559310 | 2020-07-09 | ||
| CN202010655931 | 2020-07-09 | ||
| CN202010776540 | 2020-08-07 | ||
| CN2020107765404 | 2020-08-07 | ||
| PCT/CN2021/105275 WO2022007903A1 (zh) | 2020-07-09 | 2021-07-08 | 一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115697992A true CN115697992A (zh) | 2023-02-03 |
Family
ID=79552810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180040988.2A Pending CN115697992A (zh) | 2020-07-09 | 2021-07-08 | 一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230357193A1 (zh) |
| EP (1) | EP4180427A1 (zh) |
| CN (1) | CN115697992A (zh) |
| TW (1) | TW202216684A (zh) |
| WO (1) | WO2022007903A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202346293A (zh) * | 2022-04-29 | 2023-12-01 | 大陸商四川海思科製藥有限公司 | 含氮雜環衍生物及其组合物和藥學上的應用 |
| WO2024012570A1 (zh) * | 2022-07-15 | 2024-01-18 | 西藏海思科制药有限公司 | 一种含氮杂环衍生物及其组合物和药学上的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998022432A1 (fr) * | 1996-11-18 | 1998-05-28 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'acylanilide a substitution acylamino ou composition comprenant ces derives |
| BR112017019751A2 (pt) * | 2015-03-18 | 2018-05-29 | Arvinas Inc | composto bifuncional, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou um distúrbio, e para degradar uma proteína alvo em uma célula |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| AU2018215212B2 (en) * | 2017-01-31 | 2022-06-02 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| JP2021521192A (ja) * | 2018-04-13 | 2021-08-26 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | セレブロンリガンドおよび同リガンドを含む二機能性化合物 |
| CN110963957B (zh) | 2018-09-28 | 2021-10-22 | 深圳恩多凯医药科技有限公司 | N-芳香酰胺类化合物及其制备方法和用途 |
-
2021
- 2021-07-08 WO PCT/CN2021/105275 patent/WO2022007903A1/zh unknown
- 2021-07-08 TW TW110125139A patent/TW202216684A/zh unknown
- 2021-07-08 US US18/004,708 patent/US20230357193A1/en active Pending
- 2021-07-08 CN CN202180040988.2A patent/CN115697992A/zh active Pending
- 2021-07-08 EP EP21837764.6A patent/EP4180427A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4180427A1 (en) | 2023-05-17 |
| WO2022007903A1 (zh) | 2022-01-13 |
| TW202216684A (zh) | 2022-05-01 |
| US20230357193A1 (en) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2944573T3 (es) | Antagonistas de TLR7/8 y usos de los mismos | |
| CN109963842B (zh) | 苯并咪唑类化合物激酶抑制剂及其制备方法和应用 | |
| CN102171214B (zh) | 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 | |
| CN115873067A (zh) | Ras抑制剂 | |
| EP3889145A1 (en) | 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders | |
| CN112969696A (zh) | 乙酰化书写器抑制剂的开发及其用途 | |
| EA022134B1 (ru) | 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов | |
| JP2020527577A (ja) | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 | |
| JP2021533125A (ja) | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 | |
| CA2940918A1 (en) | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-.alpha.]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-.alpha.][1,4]diazepine derivatives as ros1 inhibitors | |
| AU2019252432B2 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| CN115697992A (zh) | 一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用 | |
| TW201211053A (en) | Spiro compound and drug for activating adiponectin receptor | |
| CN112812100B (zh) | 一种具有降解btk激酶的化合物及其制备方法和药学上的应用 | |
| WO2022007824A1 (zh) | 一种具有降解btk激酶的化合物及其制备方法和药学上的应用 | |
| CN114828959B (zh) | 3-(5-甲氧基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 | |
| CN111989313A (zh) | A2a和/或a2b受体拮抗剂 | |
| WO2022111526A1 (zh) | 一种苯环衍生物及其组合物和药学上的应用 | |
| CN113999233A (zh) | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 | |
| TW202321219A (zh) | 雜環衍生物及其組合物和藥學上的應用 | |
| CN107207476B (zh) | 吲哚和氮杂吲哚衍生物及其用于神经退化性疾病中的用途 | |
| CN112745298B (zh) | 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途 | |
| CN115066423A (zh) | Pd-l1拮抗剂化合物 | |
| CN109897036B (zh) | 三唑并吡啶类化合物及其制备方法和用途 | |
| CN112390785A (zh) | 一种bet家族溴域抑制剂环衍生物及其制备方法和药学上的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20231113 Address after: 856099 Xingfu Jiayuan Economic Development Zone, Gyerba, Nedong District, Shannan City, Tibet Autonomous Region Applicant after: Tibet Haisike Pharmaceutical Co.,Ltd. Address before: 611130 Sichuan Chengdu Wenjiang District Science and Technology Park cross strait Bailey Road 136 Applicant before: SICHUAN HAISCO PHARMACEUTICAL Co.,Ltd. |